Biomedical subjects

D L Beliaev

Publications and source records attributed to D L Beliaev.

At least 19 recordsLinked to original sources

PubMed2005

[Characterization of protection mechanisms in patients with drug-resistant pulmonary tuberculosis].

Examining the performance of the local protective system has indicated that patients with drug-resistant pulmonary tuberculosis in the presence of the higher count of cytotoxic lymphocytes had the diminished activation of lymphoid elements of bronchoalveolar lavage (BAL) and decreased alveolar macrophageal production of active oxygen forms. However, there was a drastically increased formation of active oxygen forms in the BAL macrophagues during mycobacterial phagocytosis, which may result to their death. At the same time, the decreased production of gamma-interferon in the BAL cells was found in patients with drug-resistant tuberculosis (8.0 +/- 3.0 U/ml versus 10.7 +/- 2.0 U/ml). In such patients, the generation of alpha-interferon was 105.0 +/- 38.0 U/ml versus 187.0 +/- 72 U/ml in patients with tuberculosis caused by drug-resistant Mycobacterium tuberculosis. In patients with drug-resistant tuberculosis, the lower production of alpha- and gamma-interferons in the BAL cells leads to their decreased regulatory effect on the mechanisms of local defense of the lung. The drastically enhanced production of active oxygen forms, which has been ascertained in patients with drug-resistant tuberculosis, is able to result in the death of macrophages, the release of lysing enzymes into the tissues surrounding the lung; the higher count of T cytotoxic lymphocytes, the lower levels of cells in apoptosis, and mycobacterial resistance to antibacterial drugs deteriorate the course of pulmonary tuberculosis in this category of patients.

Adolescent↗

PubMed2004

[Leukinferon-induced changes in cytochemical parameters of the wound exudate neutrophilic granulocyte nucleus and cytoplasm in patients with maxillofacial phlegmons].

Clinical and cytochemical study of the wound exudate neutrophilic granulocytes (NG) in patients with maxillofacial phlegmons treated traditionally and with leukinferon (immunomodulator) added to basic therapy demonstrated a positive clinical effect and pronounced stimulation of NG in the patients treated with leukinferon. The time course of cytochemical parameters of NG cytoplasm and chromatin activity was principally different in the two groups of patients. A new tissue index of NG was developed, giving an accurate integral picture of the total biological activity of the wound exudate NG.

Adjuvants, Immunologic↗

PubMed2004

[Leukinferon in combined therapy for acute pulmonary tuberculosis].

Experiments on 140 CBA and C57BL/6 mice and studies of 163 patients with acute pulmonary tuberculosis have indicated that leukinferon has a immunomodulating effect on morphological reactions in the lung and on the clinical course of the disease. They have shown that leukinferon plays an important role in the activation of exudate macrophages and in the acceleration of their differentiation in experimental tuberculosis and that there is a rapid elimination of Mycobacterium tuberculosis from the involved organs without production of the L-forms of the causative agent when immunomodulation is used. At months 2-3, the patients with acute pulmonary tuberculosis showed the accelerated processes of detoxification, abacillation, infiltrate resolution, and decay cavity closure during hemo- and immunomodulation with the normalized production of cytokines (gamma-interferon and tumor necrosis factor-alpha). During 6-month therapy, a severe pulmonary process was arrested in 84% of cases and some patients were operated on (76% in the comparison group). The morphological effect of leukinferon was to increase mononuclear infiltration and to normalize a lung connective tissue response, by further decreasing the rate of inflammation.

Acute Disease↗

PubMed2003

[Effects of immunomodulator leukinferon on the course of experimental tuberculosis].

An experiment was conducted on 60 CBA mice intravenously inoculated with cultured Mycobacteria tuberculosis (MBT), Erdmann strain, in a dose of 0.025 mg. The specific features of tissue, cellular, and biochemical reactions were studied in the lung, liver, and spleen when leukinferon (LF) was included into tuberculosis treatment regimen. LF was shown to have a positive impact on the development of reparative reactions during tuberculous inflammation by reducing the time of abacillation and recovering the structure of diseased organs. By month 3 of follow-up, MBT were not detected in mice receiving antibacterial agents (ABA) and LF, while typical and changed forms of LF were identified in the cytoplasm of alveolar macrophages in mice treated with ABA alone. A specific feature of an inflammatory reaction as a significant proliferation of lymphocytes and macrophages with their ample infiltration of target organs was noted in animals receiving LF. This was followed by the activated production of alpha- and gamma-interferons and by the mobilization of an enzymatic link of anti-oxidant defense under chronic oxidative stress, which led to a reduction of resolution of inflammatory areas and to an increase in survival of animals which had not been given ABA, but treated with LF alone.

Adjuvants, Immunologic↗

PubMed2003

[Efficacy of leukinferon immunocorrection in patients with maxillofacial phlegmons].

Clinical and immunological studies were carried out in patients with maxillofacial phlegmons treated by traditional methods and by traditional therapy supplemented by immunocorrection (leukinferon). Addition of leukinferon to basic therapy had a pronounced clinical and immunomodulating effect, which resulted in shorter hospitalization period and virtually complete recovery of the main immunological parameters, in contrast to traditional therapy alone. The most demonstrative parameters were the expression of the neutrophil granulocyte membrane receptors and the relationships between T-lymphocyte subpopulations, which prompted using them as the most significant diagnostic markers indicating the disease severity and treatment efficiency.

Adjuvants, Immunologic↗

PubMed2002

[Leukinferon in the treatment of patients with sepsis and multiple organ dysfunction syndrome].

Dynamics of clinical signs, blood formula and some cytokins in serum samples of the patients with sepsis complicated by multiorgan disfunction syndrome (as a rule kidney and liver were involved) were investigated. Etiotropic therapy was combined with immunocorrecting treatment with leukinferone Combined regime provided positive results in clinical symptoms, in lymphocytes number normalization (abs. and per cent), stimulated T lymphocytes differentiation and facilitated intoxication finishing according to LII). Immunocorrection practically had no effect on TNF-alpha, IL-1 alpha, IL-6, and stimulated IL-8 secretion more effectively than etiotropic therapy. IF-gamma level enhanced along with stopped IL-10 production. As a result ratio of IF-gamma/IL-10 enhanced from 0.56 to 1.0, in the case of etiotropic therapy this ratio diminished from 0.48 to 0.3. It is concluded that immunocorrecting therapy provided positive dynamics in the ration IF-gamma/IL-10, recurring cell immune reactions. The recurrence period was shortened and lethality level was substantially lower (2.5 times).

Adjuvants, Immunologic↗

PubMed1995

[The use of leukinferon in treating measles in adult patients].

The following mucosal are characteristic of measles in adult patients: dryness in the oral cavity, dryness, desquamation, and fissures in the red edge and in the mouth corners, edema and hyperemia, of the buccal mucosa, macular enanthema on the hard and soft palate, Bel'skiĭ-Filatov-Koplik spots, whitish deposit on the gingiva, edematous and bleeding gingiva, and, as a result of general intoxication, a lingual deposit. Leukinferon, a wide-spectrum immunocorrective drug, was used to improve the efficacy of treatment of adult patients with measles; besides alpha-interferon, it contains other cytokines of the first phase of immune response. Therapy with leukinferon led to a sooner improvement of the general status and a more rapid regression of the disease symptoms, including changes in the buccal mucosa, in comparison with the control leukinferon-untreated group.

Acute Disease↗

PubMed1994

[Experience of immunotherapy with leukinferon in the comprehensive therapy of breast cancer].

Patients with breast tumors, stage IIb-IIIb, received complex treatment including radiation therapy, radical surgery and polychemotherapy. Some of them were also injected 4-40 doses of leukinferon, im, for immunocorrection. The latter treatment carried out during radiotherapy and preparation for surgery prevented lymphopenia development. Leukinferon administered during 6-8 courses of cytostatic polychemotherapy was followed by a significant rise in lymphocyte concentration. Leukinferon-treated patients, on the whole, revealed higher rates of postoperative rehabilitation, improved tolerance of rigorous treatment and lower frequency of metastatic development. A correlation was established between preoperative lymphocyte level and risk of metastasis development at later stages. No metastasis or recurrence was detected within 15-42 months in 16 patients who received leukinferon throughout the entire period of treatment.

Adjuvants, Immunologic↗

PubMed1994

[Leukinferon in the treatment of patients with acute viral hepatitis b].

Leukinferon activity was studied in a controlled trial including 30 patients with acute viral hepatitis. The disease ran a moderate severity course in the majority of the patients. Leukinferon, a combined preparation of natural interferon and cytokines produced by virus-induced leukocytes, has marked immunomodulating properties at moderate antiviral activity. Leukinferon was administered intramuscularly for 10 days according to the following scheme: day 1-1 sample 3 times, day 2-1 ampule 2 times, day 3-10-1 ampule a day (overall 1 x 10(5) U of interferon). Due to leukinferon the symptoms of intoxication declined, hepatic biochemistry normalized more rapidly as well as the period of viremia and antigenemia. Positive clinical trends correlated with interferon system improvement and activation of natural killers. 6 months later complete recovery was registered in all leukinferon-treated subjects.

Acute Disease↗

PubMed1994

[Prevention of postpartum inflammatory diseases in puerperae with pyelonephritis and toxemia].

Puerperae with acute and chronic pyelonephritis complicated by gestosis often develop postpartum inflammatory complications in the presence of marked deficiency of T lymphocytes and phagocytic function. Clinical criteria are suggested to single out risk groups. Prophylactic injections of leukinferon (alpha-interferon) and other immune response first phase cytokines in complex with metabolic agents help almost normalize the immunologic parameters in the majority of puerperae within 3-6 days and reduce threefold the incidence of early and late postpartum inflammatory complications.

Female↗

PubMed1993

[Leukinferon in the comprehensive therapy of sepsis in newborns].

Leukinferon was used in adoptive immunotherapy of sepsis in risk group newborns by activation of the donor leukocyte suspension in combination with etiotropic, antitoxic and other agents of chemotherapy. It accelerated the recovery at the average of 7 days in comparison with the control (the routine treatment). The favourable time course of the major immunological indices such as leukocytosis and absolute and relative counts of lymphocytes mainly due to correction of the T-lymphocyte count, NBT and LII impaired by the pathological process was recorded at the average 4 days earlier against the control. By the end of the treatment normalization of the above mentioned indices proved to be more complete. Neither complications of the septic process nor side effects of the immunotherapy were observed.

Adjuvants, Immunologic↗

PubMed1993

[The combined therapy of patients with gonorrheal-chlamydial urogenital infections by leukinferon immunocorrection].

The adjuvant injection of wide-spectrum immunocorrector leukinferon to 45 males with gonorrheal-chlamydial urogenital infection receiving tarivid and doxicicline made the treatment shorter and the number of inflammatory complications and recurrences less numerous. Leukocyte and lymphocyte counts returned to normal values 6 days earlier and so did immunological indices. In control subjects (20 patients) on immunocorrection with tactivin inflammation persisted longer, urogenital complications were not cured, chlamydial recurrences occurred in 10% of the patients, immunological normalization was not reached.

Adjuvants, Immunologic↗

PubMed1993

[The treatment of histiocytosis X (Langerhans-cell histiocytosis) with alpha-interferon preparations].

Langerhans cell histiocytosis (LCH) and histiocytosis class II (without Langerhans cells) were treated in 10 and 2 patients, respectively, with alpha-interferon preparations: recombinant alpha 2-interferon and two combined preparations containing natural alpha-interferon and immune response phase 1 cytokines. The patients' age ranged from 18 to 61 years, all of them had multiple lesions. Six of them exhibited dysfunctions of the affected organs. As shown by the results of 16-52-month follow-up, LCH patients' disease persisted in chronic active stage without progression (8 cases) or reached a complete remission (1 case), one patient died. In histiocytosis class II alpha-interferon administration was uneffective.

Adolescent↗

PubMed1992

[Leukinferon in immunological correction of acute inflammatory diseases of the abdominal organs].

Addition of (intramuscular+intravenous) leukinferon (LF) to the schemes for the treatment of acute peritonitis promoted a more rapid positive development of the time course of clinical signs and decreasing of leukocytosis in the presence of a pronounced tendency to normalization of the main immunological indices i. e. the counts of differential T-lymphocytes and T-helper cells. There was also activation of neutrophil phagocytic function. A rapid decrease in objective signs of endotoxicosis was recorded: the intoxication leukocytic index and the level of medium-mass molecules. In parallel with the decrease in the intoxication leukocytic index, there was a decrease in cytosis of the peritoneal exudate. The use of LF in the treatment of elderly patients with acute cholecystitis eliminated the clinical signs and normalized the main laboratory indices without surgical interventions which allowed one to make a planned operation with the minimum risk.

Acute Disease↗

PubMed1992

[Effects of leukinferon on the phagocytic function of puerperal blood].

Leukinferon effects on the phagocytic activities of the monocytes and polymorphonuclear leukocytes of 12 pregnant women and puerperants with various chronic infectious diseases were studied in vitro. Blood samples of 5 female donors were examined for control. It was found possible to stimulate and correct phagocytic function by leukinferon, proceeding from the initial function of the blood cells and the presence of serum factors. The immunocorrecting properties of leukinferon were found particularly valuable in cases with immunodeficiencies, for infectious diseases and labor complications could thus be prevented in this high-risk group of puerperants.

Cytokines↗

PubMed1991

[Differentiation of methicillin-resistant strains of Staphylococcus aureus by prophage specificity].

By inducing with mitomycin C the following phages were isolated from all the tested 32 methicillin resistant strains of S. aureus: the serogroup B phage was isolated from 2 strains, the serogroup B and F phages were isolated from 5 strains and the serogroup F phage was isolated from 25 strains. The phages were divided into 5 groups by the antiphage immunity. In group 1 of the phages 4 additional phages were specified. By the specificity of the prophages in the cultures all the strains were divided into 5 groups. Group 1 of the cultures was divided into 5 subgroups (A, B, C, D and E).

Bacteriophage Typing↗

PubMed1990

[The effect of injectable leukinferon on the immune reactivity of patients with steroid-dependent bronchial asthma].

The authors provide the results of the treatment with leukinferon for injections of 25 patients with steroid-dependent bronchial asthma. It is the authors' belief that leukinferon for injections may be recommended for introduction into multimodality schedules of the treatment of patients with the above-indicated pathology. The drug is tolerated well, without any phenomena of sensitization, when administered by inhalation in the form of aqueous aerosol in a dose of 10,000 IU/day. As a result of 6 to 8 injections, immunoreactivity showed a positive time-course of changes, the patients' clinical status improved, and the maintenance doses of glucocorticosteroids could be noticeably reduced.

Administration, Inhalation↗

PubMed1989

[The antigenic characteristics of Salmonella typhi L forms].

The study of the possibility of detecting the specific antigens of S. typhi L forms has revealed that out of three destructive methods under study (osmotic lysis, freezing-thawing, sonication) only ultrasonic disintegration has proved to be effective for S. typhi L forms. Three specific fractions capable of interacting only with specific antibodies to S. typhi L forms have been revealed in the course of chromatographic separation of the soluble antigenic complex of S. typhi stable L forms and the subsequent analysis of the fractions thus obtained in the enzyme immunoassay.

Antigens, Bacterial↗